Investor Q&A with Steven Yatomi-Clarke

In this session Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke discussed the key highlights:

  • An update on Prescient’s strategy and upcoming milestones, with a focus on PTX-100.
  • The journey of value creation for biotech companies, and why Prescient is on the cusp of a significant inflection point.
  • Why the data from their PTX-100 Phase 1b trial is so promising.
  • How the development pathway for PTX-100 could be considerably shorter and cheaper than conventional drug development paths.
  • How their $18m cash position allows them to go deep into a Phase 2 trial.

Recorded on 25th March 2024 at 12pm (AEDT).

Stay up to date with PTX

COMPANY UPDATES

View all

Open investments

View all

Felix Gold Ltd

Place a bid

Investment Type:

Placement

Our Role:

Alaskan high grade gold explorer with multi-million ounce potential, strategically located next to an ore-hungry mill.
Investment Overview

Asian Battery Metals (AZ9)

Request Prospectus

Investment Type:

Public Offer

Our Role:

A copper and critical battery minerals exploration company strategically positioned on the doorstep of China.
Investment Overview

Zetaris

Request Offer Docs

Investment Type:

Convertible Note

Our Role:

Aussie big data company enabling large corporations to leverage AI.
Investment Overview

upcoming events

View all

Connecting quality investors and innovative companies to facilitate mutual wealth creation with trust and transparency

Speak to an Adviser

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.

Close

Stay up to date with FEG

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged by Zetaris to manage this offer and will receive fees based on the uptake of this offer.

latest other webcasts

Xsights Innovation Nation

Zetaris Investor Briefing

Nicolab Investor Briefing

Follow PTX

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.